Alexza Pharmaceuticals, which is developing a number of inhaled drugs using its proprietary Staccato inhaler, will offer 44,000,000 shares of common stock and 44,000,000 warrants to purchase common stock at $0.50 per share for a total offer of $22 million. One warrant to purchase a common share will be sold with each common share. According to the company, the money raised will be used for general corporate purposes.
Alexza’s MAA for Adasuve Staccato loxapine for the treatment of agitation in schizophrenics is under review by the EMA, and the FDA has extended its review of the Adasuve NDA. The company is also developing Staccato loxapine for the treatment of migraine headache and four other Staccato products.
Read the Alexza press release.
View the Alexza prospectus.
